Biotech, MedTech, & Life Sciences
Companies engaged in biotechnology, medical technology, and the life sciences and healthcare information technology have unique challenges and sophisticated needs. The industry is experiencing explosive growth and faced with rapidly evolving regulations. At the same time, the discovery, development, and commercialization of new biotech and med tech products can be a long and complicated process that requires skilled negotiation and careful planning.
Drawing on the strengths of several practice areas, Jackson Walker has assembled an interdisciplinary team with specific experience serving this dynamic industry. We assist our medical technology clients in bringing products to market, financing growth, and meeting the demands of the global market. We also advise life sciences companies on both public and private equity and debt financing, mergers and acquisitions, technology licensing and contracts, intellectual property protection, and government compliance (including FDA compliance, import, export, and labeling), as well as day-to-day securities and corporate governance matters. Our clients range from established multinational drug and device companies with blockbuster products to smaller biotech startups with their first viable products. By applying our understanding of the business concerns of both growing and mature companies, we are able to develop solutions that are customized to our clients’ specific needs.
Technologies we represent include:
|
|
Recent transactions include:
- Represented HealthTronics, Inc. (HTRN) in the $20 million acquisition of Endocare Inc. (ENDP) by tender offer
- Represented a medical information technology company in a $40 million merger and sale to a private equity fund
- Represented a public healthcare and manufacturing company in its acquisitions of publicly-traded competitors
- Represented life sciences and medical technology companies with private placements
- Represented educational institutions on incubation, intellectual property, and other research and commercialization matters
Jackson Walker Represents Kalon Biotherapeutics in Sale to Fujifilm
Jackson Walker represented Kalon Biotherapeutics in its sale of control to FUJIFILM Diosynth Biotechnologies USA by the State of Texas, acting by and through the Office of the Governor and the Texas A&M University System.
Client Results • December 24, 2014
SCOTUS Simplifies Market Entry Process for Biosimilar Products
By Sara Borrelli
Today’s unanimous ruling by the U.S. Supreme Court in Sandoz v. Amgen injects much-needed certainty into a difficult statute and streamlines the process for biosimilar products to enter the marketplace following FDA approval under the Biologics Price Competition and Innovation Act (BPCIA).
Insights • June 13, 2017
Stephanie Chandler Speaks on Trends in the Biotech Industry for Entrepreneurial Success
Jackson Walker partner Stephanie Chandler will be speaking at the closing session of this year’s Emerging Medical Technology Symposium at Innotech on April 4, 2012, in San Antonio, Texas.
Attorney News • February 27, 2012
